atisnolerbart

Atisnolerbart is a **human monoclonal IgG4 antibody** targeting **Bet v 1**, the major birch pollen allergen. It is part of a clinical mixture of three monoclonal antibodies (atisnolerbart, bremzalerbart, umesolerbart), developed for the treatment of seasonal allergic diseases, particularly **allergic rhinitis and conjunctivitis** caused by birch pollen. The antibody binds specifically to Bet v 1, neutralizing its ability to trigger allergic immune responses. Atisnolerbart (REGN5715) is developed using fully human mAb sequences and is currently in phase 3 clinical trials for these indications[1][3][5].

Other names

REGN5715REGN-5715REGN 5715